| Literature DB >> 32180853 |
Payam Mehrian1, Poopak Farnia2,3, Dina Jalalvand2, Mostafa Rezaei Chamani2, Mahmood Bakhtiyari2.
Abstract
PURPOSE: Multi-drug-resistant tuberculosis (MDR-TB) is simultaneously resistant to isoniazid and rifampin. Of course, this germ may also be resistant to other anti-tuberculosis drugs. Patients with extensively drug-resistant tuberculosis (XDR-TB) are also resistant to all types of fluoroquinolone and at least one of the three injectable medications: amikacin, clarithromycin, or kanamycin, in addition to isoniazid and rifampin. Therefore, the main objective of the current study was to evaluate and compare the computed tomography (CT) scan findings of MDR-TB and XDR-TB patients.Entities:
Keywords: antimicrobial resistance; computerised tomography scan; tuberculosis
Year: 2020 PMID: 32180853 PMCID: PMC7064012 DOI: 10.5114/pjr.2020.93123
Source DB: PubMed Journal: Pol J Radiol ISSN: 1733-134X
Figure 166 year-old male with extensively drug-resistant tuberculosis. Axial computed tomography scan of the lung showing cavitary consolidation with airbronchogram in left lower lobe
Figure 621 year-old female with extensively drug-resistant tuberculosis. Lung window computed tomography scan showing a cavitary lesion with air-fluid level (black arrow) associated with bronchiectasis in right upper lobe. Note also the fibrocavitary lesion involving left upper lobe
Figure 351 year-old male with multi-drug-resistant tuberculosis. Axial computed tomography scan of the lung showing consolidation in right middle lobe with extensive nodular infilteration
Cavitary lesions across the groups
| Variable | MDR-TB | XDR-TB | |
|---|---|---|---|
| Cavitary | 24 (85.7%) | 13 (76.5%) | 0.43 |
| Pattern | |||
| In nodule and mass | 16 (57.1%) | 12 (70.6%) | 0.36 |
| In consolidation | 12 (42.9%) | 6 (35.3%) | 0.61 |
| In nodule and mass plus consolidation | 4 (4.13%) | 5 (29.4%) | 0.21 |
| Total number | 1.5 ± 1 | 2 ± 2 | 0.39 |
| Size of largest cavitary lesion (mm) | 29 ± 25 | 45 ± 15 | 0.44 |
| Largest thickness (mm) | 5.5 ± 2 | 6 ± 2 | 0.44 |
| Laterality | |||
| Unilateral | 29 ± 25 | 9 (62.9%) | 0.12 |
| Bilateral | 5.5 ± 2 | 4 (23.5%) | 0.25 |
| Number of lobes | 1.3 ± 0.98 | 1.82 ± 1.70 | 0.20 |
| Air-fluid level | 7 (25.0%) | 5 (29.4%) | 0.74 |
Parenchymal lesions across the groups
| Variable | MDR-TB | XDR-TB | |
|---|---|---|---|
| Micronodule < 10 mm | 28 (100%) | 17 (100%) | 1.000 |
| Number of lobes with micronodules | 3.96 ± 1.64 | 3.47 ± 1.74 | 0.35 |
| Macronodule < 10 mm | 15 (53.6%) | 8 (47.1%) | 0.67 |
| Number of lobes with macronodules | 1 (0-2) | 0 (0-1) | 0.58 |
| TIB | 23 (82.1%) | 15 (88.2) | 0.58 |
| Number of lobes with TIB | 2.71 ± 1.95 | 2 (1-2) | 0.83 |
| Ground glass opacity and consolidation | 18 (64.3%) | 15 (88.2%) | 0.07 |
| Number of lobes with ground glass opacity and consolidation | 1 (0-2) | 2 (1-2) | 0.10 |
| Bronchiectasis | 23 (82.1%) | 15 (88.2%) | 0.58 |
| Number of lobes with bronchiectasis | 1 (0-2) | 2 (1-3) | 0.17 |
| Cicatricial emphysema | 4 (14.3%) | 2 (11.8%) | 0.80 |
| Number of lobes with cicatricial emphysema | – | – | 0.85 |
| Parenchymal calcification | 8 (28.6%) | 11 (64.7%) | 0.01 |
| Number of lobes with parenchymal calcification | 0.5 ± 0.18 | 0.76 ± 0.16 | 0.32 |
| Lobar atelectasis | 4 (14.3%) | 3 (17.6%) | 0.76 |
| Number of lobes with lobar atelectasis | – | – | 0.70 |
Mean ± SD tested by independent sample t-test
Median and IQR tested by Mann-Whitney U test
χ2 test
Extra-parenchymal lesions across the groups
| Variable | MDR-TB | XDR-TB | |
|---|---|---|---|
| Mediastinal lymphadenopathy | 17 (60.7%) | 10 (58.8%) | 0.90 |
| Pericardial effusion | 2 (7.1%) | 3 (17.6%) | 0.27 |
| Hilar lymphadenopathy | 12 (43%) | 10 (58.8%) | 0.29 |
| Hilar lymphadenopathy laterality | |||
| Unilateral | 9 (32.1%) | 9 (52.9%) | 0.16 |
| Bilateral | 3 (10.7%) | 1 (5.9%) | 0.58 |
| Not seen | 16 (57.1%) | 7 (41.2%) | 0.29 |
| Calcified lymphadenopathy | 3 (10.7%) | 5 (29.4%) | 0.11 |
| Pleural effusion | 20 (71.7%) | 16 (94.1%) | 0.06 |
| Pleural effusion laterality | |||
| Unilateral | 15 (53.6%) | 14 (82.4%) | 0.051 |
| Bilateral | 5 (17.9%) | 2 (11.8%) | 0.58 |
| No effusion | 8 (28.6%) | 1 (5.9%) | 0.06 |
| Loculated pleural effusion | 3 (10.7%) | 3 (10.7%) | 0.58 |